Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has received an average rating of "Moderate Buy" from the thirteen brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $69.46.
A number of brokerages have recently commented on RYTM. Needham & Company LLC boosted their price target on Rhythm Pharmaceuticals from $64.00 to $66.00 and gave the stock a "buy" rating in a research report on Tuesday, March 18th. Canaccord Genuity Group increased their target price on Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday, March 24th. Morgan Stanley reissued an "overweight" rating and set a $72.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Friday, March 7th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $75.00 target price on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd.
View Our Latest Analysis on RYTM
Rhythm Pharmaceuticals Trading Up 2.2 %
RYTM traded up $1.08 during trading on Friday, reaching $51.08. The stock had a trading volume of 307,886 shares, compared to its average volume of 509,919. The company has a market capitalization of $3.23 billion, a price-to-earnings ratio of -11.80 and a beta of 2.30. The stock's 50 day moving average is $55.22 and its two-hundred day moving average is $55.14. Rhythm Pharmaceuticals has a one year low of $35.17 and a one year high of $68.58.
Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The business had revenue of $41.83 million during the quarter, compared to the consensus estimate of $38.48 million. On average, equities research analysts predict that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current year.
Insider Activity
In other Rhythm Pharmaceuticals news, EVP Yann Mazabraud sold 75,000 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the completion of the sale, the executive vice president now directly owns 40,370 shares of the company's stock, valued at approximately $2,078,247.60. This represents a 65.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Hunter C. Smith sold 1,678 shares of Rhythm Pharmaceuticals stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total transaction of $99,723.54. Following the transaction, the chief financial officer now owns 101,186 shares in the company, valued at $6,013,483.98. This represents a 1.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 108,131 shares of company stock valued at $5,781,098 in the last quarter. 5.60% of the stock is currently owned by insiders.
Institutional Trading of Rhythm Pharmaceuticals
Hedge funds have recently bought and sold shares of the stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Rhythm Pharmaceuticals during the 4th quarter valued at about $4,259,000. GF Fund Management CO. LTD. bought a new stake in Rhythm Pharmaceuticals during the 4th quarter worth approximately $72,000. Voloridge Investment Management LLC lifted its holdings in Rhythm Pharmaceuticals by 7.7% during the fourth quarter. Voloridge Investment Management LLC now owns 380,537 shares of the company's stock valued at $21,302,000 after purchasing an additional 27,214 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Rhythm Pharmaceuticals by 2.3% in the fourth quarter. Two Sigma Advisers LP now owns 13,100 shares of the company's stock worth $733,000 after purchasing an additional 300 shares during the period. Finally, State of Wyoming purchased a new stake in shares of Rhythm Pharmaceuticals in the fourth quarter worth $61,000.
About Rhythm Pharmaceuticals
(
Get Free ReportRhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
Further Reading

Before you consider Rhythm Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.
While Rhythm Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.